Fei Zhou

5.7k total citations
122 papers, 3.3k citations indexed

About

Fei Zhou is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Fei Zhou has authored 122 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Pulmonary and Respiratory Medicine, 69 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Fei Zhou's work include Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (40 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Fei Zhou is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Lung Cancer Research Studies (40 papers) and Cancer Immunotherapy and Biomarkers (25 papers). Fei Zhou collaborates with scholars based in China, United States and Taiwan. Fei Zhou's co-authors include Caicun Zhou, Xuefei Li, Tao Jiang, Shengxiang Ren, Chunxia Su, Chao Zhao, Meng Qiao, Guanghui Gao, Xiaoxia Chen and Xiaomei Gong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Fei Zhou

116 papers receiving 3.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fei Zhou China 31 1.9k 1.7k 885 597 376 122 3.3k
Tina Cascone United States 30 1.8k 1.0× 1.6k 0.9× 1.4k 1.5× 684 1.1× 331 0.9× 104 3.4k
Xiuning Le United States 32 1.8k 0.9× 2.0k 1.2× 1.3k 1.4× 619 1.0× 235 0.6× 168 3.5k
Yoon Jin South Korea 29 1.1k 0.6× 898 0.5× 912 1.0× 718 1.2× 298 0.8× 178 3.0k
Zaoqu Liu China 32 1.2k 0.6× 1.2k 0.7× 1.5k 1.7× 1.1k 1.8× 826 2.2× 142 3.4k
David Garfield United States 22 1.1k 0.6× 1.2k 0.7× 769 0.9× 622 1.0× 235 0.6× 52 2.4k
Gregory M. Coté United States 35 1.3k 0.7× 1.4k 0.8× 1.3k 1.4× 485 0.8× 345 0.9× 151 3.4k
Vincenzo Damiano Italy 26 1.9k 1.0× 1.2k 0.7× 1.4k 1.5× 459 0.8× 201 0.5× 62 3.2k
Akhil Chawla United States 13 1.9k 1.0× 570 0.3× 614 0.7× 638 1.1× 558 1.5× 44 2.5k
Yutaka Hatanaka Japan 27 1.2k 0.6× 653 0.4× 712 0.8× 533 0.9× 303 0.8× 143 2.2k
Sigve Andersen Norway 33 2.0k 1.0× 1.2k 0.7× 1.6k 1.8× 1.4k 2.3× 981 2.6× 80 3.9k

Countries citing papers authored by Fei Zhou

Since Specialization
Citations

This map shows the geographic impact of Fei Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fei Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fei Zhou more than expected).

Fields of papers citing papers by Fei Zhou

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fei Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fei Zhou. The network helps show where Fei Zhou may publish in the future.

Co-authorship network of co-authors of Fei Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Fei Zhou. A scholar is included among the top collaborators of Fei Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fei Zhou. Fei Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Zhou, Fei, Pan Li, Xiaowei Ma, et al.. (2024). In Situ, Fusion-Free, Multiplexed Detection of Small Extracellular Vesicle miRNAs for Cancer Diagnostics. Analytical Chemistry. 96(39). 15665–15673. 9 indexed citations
3.
4.
Xiu, Weigang, Yuwen Zhou, He Du, et al.. (2023). A nomogram for the prediction of the survival of patients with advanced non‐small cell lung cancer and interstitial lung disease. Cancer Medicine. 12(10). 11375–11384. 3 indexed citations
5.
Zhou, Fei, Haoyue Guo, Xiaolong Zhou, et al.. (2022). Immune checkpoint inhibitors plus chemotherapy in patients with locally advanced or metastatic pulmonary sarcomatoid carcinoma: a multicentric real-world study. Therapeutic Advances in Medical Oncology. 14. 4287548791–4287548791. 10 indexed citations
6.
Ye, Lingyun, Yan Huang, Fei Zhou, et al.. (2022). Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Lung Cancer. 167. 25–33. 18 indexed citations
7.
Su, Chunxia, Xinxin Wang, Juan Zhou, et al.. (2021). Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer. Translational Lung Cancer Research. 10(3). 1256–1265. 15 indexed citations
8.
Zhou, Juan, Jing Zhao, Qingzhu Jia, et al.. (2021). Peripheral Blood Autoantibodies Against to Tumor-Associated Antigen Predict Clinical Outcome to Immune Checkpoint Inhibitor-Based Treatment in Advanced Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 625578–625578. 15 indexed citations
9.
10.
Zhou, Fei, Meng Qiao, & Caicun Zhou. (2020). The cutting-edge progress of immune-checkpoint blockade in lung cancer. Cellular and Molecular Immunology. 18(2). 279–293. 149 indexed citations
11.
Mao, Shiqi, Yanbiao Liu, Fei Zhou, et al.. (2019). P1.01-62 Association of Baseline Pulmonary Fibrosis with the Outcome of PD-1 Inhibitor in Patients with Advanced Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S383–S383. 1 indexed citations
12.
Li, J., et al.. (2019). P2.04-57 Predictive and Prognostic Value of CTC Monitoring in Advanced NSCLC Patients Treated with Immune Checkpoint Inhibitors. Journal of Thoracic Oncology. 14(10). S730–S730. 1 indexed citations
13.
Zhao, Sha, Xuefei Li, Chao Zhao, et al.. (2018). Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer. 128. 33–39. 34 indexed citations
14.
Luo, Jingfeng, Jiali Zhou, Fei Zhou, et al.. (2018). Combined treatment of cholangiocarcinoma with interventional radiofrequency hyperthermia and heat shock protein promoter-mediated HSV-TK gene therapy.. Europe PMC (PubMed Central). 8(8). 1595–1603. 6 indexed citations
15.
Zhou, Fei, Wenxiang Shen, Tao Jiang, et al.. (2017). Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC. Journal of Thoracic Oncology. 12(6). e65–e68. 74 indexed citations
16.
Cao, Li, Xiaohong Chen, Jing Zhao, et al.. (2017). High expression of MMP9 in glioma affects cell proliferation and is associated with patient survival rates. Oncology Letters. 13(3). 1325–1330. 83 indexed citations
17.
Jiang, Tao, Meng Qiao, Fei Zhou, et al.. (2016). Effect of Combined Therapy Inhibiting EGFR and VEGFR Pathways in Non–Small-cell Lung Cancer on Progression-free and Overall Survival. Clinical Lung Cancer. 18(4). 421–431.e3. 13 indexed citations
18.
Gao, Shane, Peng Zhao, Chao Lin, et al.. (2013). Differentiation of Human Adipose-Derived Stem Cells into Neuron-Like Cells Which Are Compatible with Photocurable Three-Dimensional Scaffolds. Tissue Engineering Part A. 20(7-8). 1271–1284. 69 indexed citations
19.
Cao, Hui, et al.. (2013). Wnt signaling pathways participate in Astragalus injection-induced differentiation of bone marrow mesenchymal stem cells. Neuroscience Letters. 553. 29–34. 6 indexed citations
20.
Zhou, Fei. (2007). Clinical Guiding Significance of Treatise on Febrile and Miscellaneous Diseases in Treating Tumors. Shanghai Journal of Traditional Chinese Medicine. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tina Cascone Breakdown of academic impact, for papers by Xiuning Le Breakdown of academic impact, for papers by Yoon Jin Breakdown of academic impact, for papers by Zaoqu Liu Breakdown of academic impact, for papers by David Garfield Breakdown of academic impact, for papers by Gregory M. Coté Breakdown of academic impact, for papers by Vincenzo Damiano Breakdown of academic impact, for papers by Akhil Chawla Breakdown of academic impact, for papers by Yutaka Hatanaka Breakdown of academic impact, for papers by Sigve Andersen
Rankless by CCL
2026